The historical rank and industry rank for TaiMed Biologics's Pretax Margin % or its related term are showing as below:
ROCO:4147'
s Pretax Margin % Range Over the Past 10 Years
Min: -13581.98 Med: -64.99 Max: -25.37
Current: -27.44
ROCO:4147's Pretax Margin % is ranked better than 60.81% of 939
companies
in the Biotechnology industry
Industry Median: -89.42
vs ROCO:4147: -27.44
TaiMed Biologics (ROCO:4147) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
TaiMed Biologics Pretax Margin % Related Terms
TaiMed Biologics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, TaiMed Biologics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a Pretax Margin % of -45.72% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #368 out of 939 companies in the Biotechnology industry, placing it in the top 39.2%.
Is TaiMed Biologics' Pretax Margin % too high?
TaiMed Biologics' current Pretax Margin % is -45.72%. Based on the distribution chart, TaiMed Biologics ranks #368 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #368 out of 939 companies for Pretax Margin %. This puts TaiMed Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current Pretax Margin % is -45.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Pretax Margin % is -45.72%. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Pretax Margin % is -45.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Pretax Margin %: -45.72%
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
